DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Hydrochlorothiazide; valsartanis the generic ingredient in two branded drugs marketed by Novartis, Alembic Pharms Ltd, Apotex Inc, Aurobindo Pharma Ltd, Lupin Ltd, Macleods Pharms Ltd, Mylan Pharms Inc, Prinston Inc, Watson Labs Teva, and Zydus Pharms, and is included in ten NDAs. Additional information is available in the individual branded drug profile pages.
There are thirty-two drug master file entries for hydrochlorothiazide; valsartan. Sixteen suppliers are listed for this compound. There is one tentative approval for this compound.
Summary for HYDROCHLOROTHIAZIDE; VALSARTAN
|Drug Master File Entries:||32|
|Suppliers / Packagers:||16|
|Bulk Api Vendors:||1|
|Patent Litigation and PTAB cases:||See patent lawsuits and PTAB cases for HYDROCHLOROTHIAZIDE; VALSARTAN|
|DailyMed Link:||HYDROCHLOROTHIAZIDE; VALSARTAN at DailyMed|
Recent Clinical Trials for HYDROCHLOROTHIAZIDE; VALSARTAN
Identify potential brand extensions & 505(b)(2) entrants
|Farma de Colombia SA||Phase 3|
|Tehran University of Medical Sciences||Phase 3|
Generic filers with tentative approvals for HYDROCHLOROTHIAZIDE; VALSARTAN
The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.
Pharmacology for HYDROCHLOROTHIAZIDE; VALSARTAN
|Drug Class||Angiotensin 2 Receptor Blocker |
|Mechanism of Action||Angiotensin 2 Receptor Antagonists |
|Physiological Effect||Increased Diuresis |
|Applicant||Tradename||Generic Name||Dosage||NDA||Approval Date||Patent No.||Patent Expiration|
|Novartis||DIOVAN HCT||hydrochlorothiazide; valsartan||TABLET;ORAL||020818-004||Apr 28, 2006||Start Trial||Start Trial|
|Novartis||DIOVAN HCT||hydrochlorothiazide; valsartan||TABLET;ORAL||020818-001||Mar 6, 1998||Start Trial||Start Trial|
|Novartis||DIOVAN HCT||hydrochlorothiazide; valsartan||TABLET;ORAL||020818-003||Jan 17, 2002||Start Trial||Start Trial|
|Novartis||DIOVAN HCT||hydrochlorothiazide; valsartan||TABLET;ORAL||020818-002||Mar 6, 1998||Start Trial||Start Trial|
|Novartis||DIOVAN HCT||hydrochlorothiazide; valsartan||TABLET;ORAL||020818-005||Apr 28, 2006||Start Trial||Start Trial|
|>Applicant||>Tradename||>Generic Name||>Dosage||>NDA||>Approval Date||>Patent No.||>Patent Expiration|
Make Better Decisions: Try a trial or see plans & pricing
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.